Product Description
HemaMax, a recombinant human interleukin-12 (IL-12), is under development to address an unmet medical need for effective treatments against acute radiation syndrome due to radiological terrorism or accident when administered at least 24 hours after radiation exposure. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3286478/)
Mechanisms of Action: IL12 Inhibitor
Novel Mechanism: No
Modality: Coagulation Factor
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: United Arab Emirates
Approved Indications: None
Known Adverse Events: None
Company: Neumedicines
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Diffuse Large B-Cell Lymphoma|Acute Radiation Syndrome|T-Cell Cutaneous Lymphoma|Mycosis Fungoides|Sezary Syndrome|Injuries/wounds Unspecified
Phase 1: Acute Radiation Syndrome
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01742221 |
NCT01742221 | P1 |
Completed |
Acute Radiation Syndrome |
2012-11-01 |
2019-03-22 |
Treatments |
|
NCT02542124 |
TSEBT | P2 |
Unknown status |
T-Cell Cutaneous Lymphoma|Sezary Syndrome|Mycosis Fungoides |
2019-02-01 |
48% |
2020-11-04 |
|
NCT02544061 |
2015-SWI-004 | P2 |
Completed |
Injuries/wounds Unspecified |
2017-10-31 |
2025-08-27 |
||
NCT02544724 |
NM-ONC-002 | P2 |
Unknown status |
Diffuse Large B-Cell Lymphoma |
2017-08-01 |
2019-03-20 |
Treatments |
|
NCT02343133 |
#HHSO100201100037C | P2 |
Completed |
Acute Radiation Syndrome |
2016-04-01 |
2019-03-20 |
Treatments |